A PHASE 1 DOSE ESCALATION AND EXPANDED COHORT STUDY OF EPZ-5676 IN THE TREATMENT OF PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY LEUKEMIAS BEARING A REARRANGEMENT OF THE MLL GENE

Registry ID

EPZ-5676-12-002

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

EPIZYME, INC.

Start date

2014-10-09

Last update

2014-08-27

Conditions

• ACUTE LYMPHOBLASTIC LEUKEMIA
• ACUTE MYELOGENOUS LEUKEMIA

Related clinical trials

• A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
• A MODULAR PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, IMMUNOGENICITY, AND PRELIMINARY EFFICACY OF AZD4512 MONOTHERAPY OR IN COMBINATION WITH ANTICANCER AGENT(S) IN PARTICIPANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
• RE-TREATMENT WITH SECOND GENERATION, ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS IN RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ACIT001-3)
• A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AZD0486 IN ADOLESCENT AND ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
• A RANDOMIZED TRIAL OF LEVOCARNITINE PROPHYLAXIS TO PREVENT ASPARAGINASE-ASSOCIATED HEPATOTOXICITY IN ADOLESCENTS AND YOUNG ADULTS RECEIVING ACUTE LYMPHOBLASTIC LEUKEMIA THERAPY
• A PHASE 1/2 FIRST IN HUMAN STUDY OF THE MENIN-MLL (KMT2A) INHIBITOR KO 539 IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

View on source registry